PharmaEngineROCO:4162 -1.86%79 EBITDA Margin % is 59.62% as of Dec. 2025, which is 10% below its 10-year median of 66.39. GuruFocus rates ROCO:4162 with a GF Score™ of 79/100 and a GF Value™ of NT$114.87 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, PharmaEngine ranks better than 95.44% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. PharmaEngine's EBITDA for the
three
months ended in Dec. 2025 was NT$170.0 Mil. PharmaEngine's Revenue for the
three
months ended in Dec. 2025 was NT$285.1 Mil. Therefore, PharmaEngine's EBITDA margin for the quarter that ended in Dec. 2025 was 59.62%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PharmaEngine EBITDA Margin % Related Terms
PharmaEngine EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PharmaEngine's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4162 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, PharmaEngine's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaEngine EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaEngine's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PharmaEngine's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaEngine (ROCO:4162) has a EBITDA Margin % of 59.62% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PharmaEngine and its competitors. This is 10% below median its historical median of 66.39. Over the past decade, PharmaEngine's EBITDA Margin % has ranged from 17.99 to 86.10. According to the industry distribution chart, PharmaEngine ranks #43 out of 944 companies in the Biotechnology industry, placing it in the top 4.6%.
Is PharmaEngine's EBITDA Margin % too high?
PharmaEngine's current EBITDA Margin % of 59.62% is 10% below median its 10-year median of 66.39. Over the past 10 years, this metric has ranged from a low of 17.99 to a high of 86.10. Based on the distribution chart, PharmaEngine ranks #43 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PharmaEngine has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PharmaEngine's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PharmaEngine ranks #43 out of 944 companies for EBITDA Margin %. This places PharmaEngine in the top 5% of its industry — outperforming the majority of peers. Historically, PharmaEngine's own EBITDA Margin % has ranged from 17.99 to 86.10 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PharmaEngine and its competitors. PharmaEngine's current EBITDA Margin % is 59.62%, which is 10% below median its own 10-year median of 66.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEngine stock overvalued right now?
Based on GuruFocus' analysis, PharmaEngine (ROCO:4162) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$114.87, compared to a current price of NT$57.90 — trading 49.6% below its estimated fair value. The current EBITDA Margin % is 59.62%, which is 10% below median its 10-year median of 66.39. PharmaEngine's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PharmaEngine (ROCO:4162), the current EBITDA Margin % is 59.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaEngine (ROCO:4162) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaEngine stock appears to be undervalued.
The current stock price of NT$57.90 is trading 49.6% below its estimated GF Value™ of NT$114.87.
GuruFocus considers PharmaEngine to be Significantly Undervalued.
Key valuation signals for ROCO:4162:
EBITDA Margin %: 59.62% (10% below median its 10-year median of 66.39)
GF Value™: NT$114.87 vs. price of NT$57.90 (49.6% below fair value)
No single metric tells the full story. See the ROCO:4162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
79GF Score
Get the complete analysis for ROCO:4162
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4162 has been successfully added to your 
